12-03-2020 дата публикации
Номер: US20200078555A1
Apparatuses and methods described herein relate to treating cancerous tumors using radiation therapy and chemotherapy. In some embodiments, a method of treatment includes administering radiation therapy targeting a tumor, isolating a segment of a vessel proximate to the tumor, and administering a dose of a chemotherapeutic agent to the segment of the vessel. The method can further include waiting a period of time after administering the radiation therapy before administering the dose of the chemotherapeutic agent. In some embodiments, a catheter device including first and second occluding elements can be used to isolate the segment of the vessel. 1. A chemotherapeutic agent comprising one or more compounds selected from any of: doxorubicin , erlotinib hydrochloride , everolimus , 5-FU , flurouracil , folfirinox , gemcitabine hydrochloride , gemcitabine-cisplatin , gemcitabine-oxaliplatin , irinotecan hydrochloride liposome , leucovorin , mitomycin C , mitozytrex , mutamycin , oxaliplatin , paclitaxel , paclitaxel albumin-stabilized nanoparticle formulation , or sunitinab malate , for use in treatment of a tumor , wherein the chemotherapeutic agent is administered subsequent to a course of radiation therapy applied to tissue surrounding the tumor after a period of time sufficient for the radiation therapy to reduce or devascularize the tissue.2. The chemotherapeutic agent of claim 1 , wherein the chemotherapeutic agent includes at least two compounds selected from any of: doxorubicin claim 1 , erlotinib hydrochloride claim 1 , everolimus claim 1 , 5-FU claim 1 , flurouracil claim 1 , folfirinox claim 1 , gemcitabine hydrochloride claim 1 , gemcitabine-cisplatin claim 1 , gemcitabine-oxaliplatin claim 1 , irinotecan hydrochloride liposome claim 1 , leucovorin claim 1 , mitomycin C claim 1 , mitozytrex claim 1 , mutamycin claim 1 , oxaliplatin claim 1 , paclitaxel claim 1 , paclitaxel albumin-stabilized nanoparticle formulation claim 1 , or sunitinab malate.3. The ...
Подробнее